Polycythemia Vera (PV): Update on Emerging Treatment Options

Giulia Benevolo, Francesco Vassallo, Irene Urbino, Valentina Giai Division of Haematology, Città della Salute e della Scienza, Turin, ItalyCorrespondence: Giulia BenevoloHematology, Città della Salute e della Scienza, Corso Bramante 88/90, Turin, 10126, ItalyEmail gbenevolo@cit...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Benevolo G, Vassallo F, Urbino I, Giai V
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	polycythemia vera therapy ruxolitinib interferon givinostat Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/58310b20c1764f47a020ac0567c74896
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:58310b20c1764f47a020ac0567c74896
record_format	dspace
spelling	oai:doaj.org-article:58310b20c1764f47a020ac0567c748962021-12-02T14:11:52ZPolycythemia Vera (PV): Update on Emerging Treatment Options1178-203Xhttps://doaj.org/article/58310b20c1764f47a020ac0567c748962021-03-01T00:00:00Zhttps://www.dovepress.com/polycythemia-vera-pv-update-on-emerging-treatment-options-peer-reviewed-article-TCRMhttps://doaj.org/toc/1178-203XGiulia Benevolo, Francesco Vassallo, Irene Urbino, Valentina Giai Division of Haematology, Città della Salute e della Scienza, Turin, ItalyCorrespondence: Giulia BenevoloHematology, Città della Salute e della Scienza, Corso Bramante 88/90, Turin, 10126, ItalyEmail gbenevolo@cittadellasalute.to.itAbstract: Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm characterized by exuberant red cell production leading to a broad range of symptoms that compromise quality of life and productivity of patients. PV reduces survival expectation, primarily due to thrombotic events, transformation to blast phase and post-PV myelofibrosis or to development of second cancers, which are associates with poor prognosis. Current therapeutic first line recommendations based on risk adapted classification divided patients into two groups, according to age (< or > 60 years) and presence of prior thrombotic events. Low-risk patients (age < 60 years and no prior history of thrombosis) should be treated with aspirin (81– 100 mg/d) and phlebotomy, to maintain hematocrit < 45%. High-risk patients (age > 60 years and/or prior history of thrombosis), in addition to aspirin and phlebotomies, should receive cytoreductive therapy in order to reduce thrombotic risk. Nowadays hydroxyurea still remains the cytoreductive agent of first choice, reserving Interferon to young patients or childbearing women. During the last years, ruxolitinib emerged as a new treatment in PV patients, as second line therapy: it appeared especially effective in patients with severe pruritus, symptomatic splenomegaly, or post-PV myelofibrosis symptoms. Currently, in PV treatment, several molecules have been tested or are under investigation. At present, the drug that has shown the most encouraging results is givinostat.Keywords: polycythemia vera, therapy, ruxolitinib, interferon, givinostatBenevolo GVassallo FUrbino IGiai VDove Medical Pressarticlepolycythemia veratherapyruxolitinibinterferongivinostatTherapeutics. PharmacologyRM1-950ENTherapeutics and Clinical Risk Management, Vol Volume 17, Pp 209-221 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	polycythemia vera therapy ruxolitinib interferon givinostat Therapeutics. Pharmacology RM1-950
spellingShingle	polycythemia vera therapy ruxolitinib interferon givinostat Therapeutics. Pharmacology RM1-950 Benevolo G Vassallo F Urbino I Giai V Polycythemia Vera (PV): Update on Emerging Treatment Options
description	Giulia Benevolo, Francesco Vassallo, Irene Urbino, Valentina Giai Division of Haematology, Città della Salute e della Scienza, Turin, ItalyCorrespondence: Giulia BenevoloHematology, Città della Salute e della Scienza, Corso Bramante 88/90, Turin, 10126, ItalyEmail gbenevolo@cittadellasalute.to.itAbstract: Polycythemia Vera (PV) is a chronic myeloproliferative neoplasm characterized by exuberant red cell production leading to a broad range of symptoms that compromise quality of life and productivity of patients. PV reduces survival expectation, primarily due to thrombotic events, transformation to blast phase and post-PV myelofibrosis or to development of second cancers, which are associates with poor prognosis. Current therapeutic first line recommendations based on risk adapted classification divided patients into two groups, according to age (< or > 60 years) and presence of prior thrombotic events. Low-risk patients (age < 60 years and no prior history of thrombosis) should be treated with aspirin (81– 100 mg/d) and phlebotomy, to maintain hematocrit < 45%. High-risk patients (age > 60 years and/or prior history of thrombosis), in addition to aspirin and phlebotomies, should receive cytoreductive therapy in order to reduce thrombotic risk. Nowadays hydroxyurea still remains the cytoreductive agent of first choice, reserving Interferon to young patients or childbearing women. During the last years, ruxolitinib emerged as a new treatment in PV patients, as second line therapy: it appeared especially effective in patients with severe pruritus, symptomatic splenomegaly, or post-PV myelofibrosis symptoms. Currently, in PV treatment, several molecules have been tested or are under investigation. At present, the drug that has shown the most encouraging results is givinostat.Keywords: polycythemia vera, therapy, ruxolitinib, interferon, givinostat
format	article
author	Benevolo G Vassallo F Urbino I Giai V
author_facet	Benevolo G Vassallo F Urbino I Giai V
author_sort	Benevolo G
title	Polycythemia Vera (PV): Update on Emerging Treatment Options
title_short	Polycythemia Vera (PV): Update on Emerging Treatment Options
title_full	Polycythemia Vera (PV): Update on Emerging Treatment Options
title_fullStr	Polycythemia Vera (PV): Update on Emerging Treatment Options
title_full_unstemmed	Polycythemia Vera (PV): Update on Emerging Treatment Options
title_sort	polycythemia vera (pv): update on emerging treatment options
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/58310b20c1764f47a020ac0567c74896
work_keys_str_mv	AT benevolog polycythemiaverapvupdateonemergingtreatmentoptions AT vassallof polycythemiaverapvupdateonemergingtreatmentoptions AT urbinoi polycythemiaverapvupdateonemergingtreatmentoptions AT giaiv polycythemiaverapvupdateonemergingtreatmentoptions
_version_	1718391842879307776

Polycythemia Vera (PV): Update on Emerging Treatment Options

Ejemplares similares